Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 124

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

de Jonge, Maja, de Weger, Vincent A., Dickson, Mark A., Langenberg, Marlies, Le Cesne, Axel, Wagner, Andrew J., Hsu, Karl, Zheng, Wei, Macé, Sandrine, Tuffal, Gilles, Thomas, Koruth, Schellens, Jan H.M.·2017·European Journal of Cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2017.02.005

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 10

  1. Wu, 1993, The p53-mdm-2 autoregulatory feedback loop, Genes Dev, 7, 1126, 10.1101/gad.7.7a.1126 · DOI · Paper page
  2. Bond, 2005, MDM2 is a central node in the p53 pathway: 12 years and counting, Curr Cancer Drug Targets, 5, 3, 10.2174/1568009053332627 · DOI · Paper page
  3. Leach, 1993, p53 mutation and MDM2 amplification in human soft tissue sarcomas, Cancer Res, 53, 2231
  4. Momand, 1998, The MDM2 gene amplification database, Nucleic Acids Res, 26, 3453, 10.1093/nar/26.15.3453 · DOI · Paper page
  5. Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 · DOI · Paper page
  6. Jung, 2016, TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma, Nat Commun, 7, 12609, 10.1038/ncomms12609 · DOI · Paper page
  7. Siu, 2014, Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors, J Clin Oncol, 32
  8. Demetri, 2016, Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial, J Clin Oncol, 34, 786, 10.1200/JCO.2015.62.4734 · DOI · Paper page
  9. Schoffski, 2016, Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial, Lancet, 387, 1629, 10.1016/S0140-6736(15)01283-0 · DOI · Paper page
  10. van der Graaf, 2012, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 379, 1879, 10.1016/S0140-6736(12)60651-5 · DOI · Paper page

Cited by

Metadata

Authors
de Jonge, M., de Weger, V. A., Dickson, M. A., Langenberg, M., Le Cesne, A., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., Thomas, K., & Schellens, J. H. M.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2017-05
Volume
76
Pages
144-151
ISSN
0959-8049
Cited by
124
References
8
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Sanofi

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.